Key result
Early SGLT2i initiation in stabilized acute heart failure improves diuretic efficiency despite inconsistent readmission effects.
Why the study?
Traditional therapies for acute heart failure remain unsatisfactory for reducing mortality and rehospitalization, leaving unresolved questions regarding the optimal timing and safety of SGLT2 inhibitors.
Do SGLT2 inhibitors improve outcomes and relieve congestion in patients with acute heart failure?
Do SGLT2 inhibitors improve outcomes and relieve congestion in patients with acute heart failure?
This narrative review highlights that early initiation of SGLT2 inhibitors in acute heart failure is generally safe and effective for congestion relief and reducing HF events, though optimal timing and specific population safety require further research.
May support SGLT2 inhibitor evaluation in AHF; leaves open whether chronic HF benefits extend to acute decompensation.
Acute heart failure (AHF) is the main cause of hospitalization in patients with heart failure (HF). Although traditional therapies play an important role in symptom relief, their efficacy in reducing mortality, rehospitalization rates, and improving long-term prognosis remains unsatisfactory. In recent years, sodium‑glucose cotransporter 2 (SGLT2) inhibitors, originally developed as glucose‑lowering agents, have demonstrated significant benefits in chronic heart failure, and their potential utility in AHF is attracting increasing attention. Current evidence indicates that early initiation of SGLT2 inhibitors in patients with AHF is generally safe, improving diuretic efficiency, relieving congestion, and reducing the risk of heart failure events. However, findings on short‑term readmission rates remain inconsistent across studies. Furthermore, unresolved issues persist regarding the optimal timing of initiation and safety in specific patient populations. This narrative review summarizes the available evidence up to 31 March 2026, with emphasis on key clinical trials, including DAPA ACT HF-TIMI 68, and selected real-world studies. We discuss the potential benefits, safety considerations, unresolved controversies, and evidence gaps regarding the use of SGLT2 inhibitors in AHF, aiming to provide a clinically oriented reference for future research and practice.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a review in Acute heart failure. SGLT2 inhibitors vs. Standard care or placebo was evaluated. Early initiation of SGLT2 inhibitors in hemodynamically stabilized patients with acute heart failure improves diuretic efficiency and relieves congestion, though effects on short-term readmission remain inconsistent.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: